Literature DB >> 11156386

Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells.

I Baba1, S Shirasawa, R Iwamoto, K Okumura, T Tsunoda, M Nishioka, K Fukuyama, K Yamamoto, E Mekada, T Sasazuki.   

Abstract

To identify the genes located downstream of the activated Ki-Ras signaling pathways in human colon cancer cells, a PCR-based cDNA subtraction library was constructed between HCT116 cells and HCT116-derived activated Ki-ras-disrupted cells (HKe3). One of the genes in HCT116 that was evidently up-regulated was epiregulin, a member of the epidermal growth factor family that is expressed in many kinds of human cancer cells. HKe3-stable transfectants expressing activated Ki-Ras regained over-expression of epiregulin. To further elucidate the biochemical structure and significance of epiregulin expression in tumorigenesis, HKe3-stable transfectants expressing epiregulin (e3-pSE cells) were established. Epiregulin existed as highly glycosylated membrane-bound forms, and TPA rapidly induced ectodomain shedding of epiregulin. Furthermore, the conditioned medium of e3-pSE cells showed more DNA synthesis for 32D cells expressing epidermal growth factor receptor (DER) cells than that of HKe3. Although anchorage-independent growth in soft agar was not observed for e3-pSE cells, tumorigenicity in nude mice was observed evidently, and their growth rate was correlated with each amount of exogenous epiregulin expression. These results suggested that activated Ki-Ras will be one of the factors contributing to the overexpression of epiregulin in human colon cancer cells, and that epiregulin will play a critical role in human tumorigenesis in vivo.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11156386

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  33 in total

1.  Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model.

Authors:  Toshiyuki Tsunoda; Yasuo Takashima; Takahiro Fujimoto; Midori Koyanagi; Yasuhiro Yoshida; Keiko Doi; Yoko Tanaka; Masahide Kuroki; Takehiko Sasazuki; Senji Shirasawa
Journal:  Neoplasia       Date:  2010-05       Impact factor: 5.715

2.  A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

Authors:  Yuli Wang; Keri Van Becelaere; Ping Jiang; Sally Przybranowski; Charles Omer; Judith Sebolt-Leopold
Journal:  Neoplasia       Date:  2005-04       Impact factor: 5.715

Review 3.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

Review 4.  Trafficking of epidermal growth factor receptor ligands in polarized epithelial cells.

Authors:  Bhuminder Singh; Robert J Coffey
Journal:  Annu Rev Physiol       Date:  2013-11-08       Impact factor: 19.318

5.  Study on the mechanism of epidermal growth factor-induced proliferation of hepatoma cells.

Authors:  Bin-Wen Wu; Yuan Wu; Jia-Long Wang; Ju-Sheng Lin; Shu-Yu Yuan; Ai Li; Wu-Ren Cui
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

Review 6.  EGFR and colon cancer: a clinical view.

Authors:  J de Castro-Carpeño; C Belda-Iniesta; E Casado Sáenz; E Hernández Agudo; J Feliu Batlle; M González Barón
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

7.  Endothelin-1 (ET-1) increases the expression of remodeling genes in vascular smooth muscle through linked calcium and cAMP pathways: role of a phospholipase A(2)(cPLA(2))/cyclooxygenase-2 (COX-2)/prostacyclin receptor-dependent autocrine loop.

Authors:  Karl Deacon; Alan J Knox
Journal:  J Biol Chem       Date:  2010-05-07       Impact factor: 5.157

8.  Transformation of polarized epithelial cells by apical mistrafficking of epiregulin.

Authors:  Bhuminder Singh; Galina Bogatcheva; Mary Kay Washington; Robert J Coffey
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-13       Impact factor: 11.205

9.  Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.

Authors:  N Sunaga; K Kaira; H Imai; K Shimizu; T Nakano; D S Shames; L Girard; J Soh; M Sato; Y Iwasaki; T Ishizuka; A F Gazdar; J D Minna; M Mori
Journal:  Oncogene       Date:  2012-09-10       Impact factor: 9.867

10.  Transcriptomic analysis of pathways regulated by toll-like receptor 4 in a murine model of chronic pulmonary inflammation and carcinogenesis.

Authors:  Alison K Bauer; Jennifer Fostel; Laura M Degraff; Elizabeth A Rondini; Christopher Walker; Sherry F Grissom; Julie Foley; Steven R Kleeberger
Journal:  Mol Cancer       Date:  2009-11-19       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.